Crizanlizumab

Crizanlizumab

Form: IV Infusion

Strength: 100 mg/10 mL (10 mg/mL)

Reference Brands: Adakveo®(EU & US)

Category: Anemia

rizanlizumab (Adakveo®) is a breakthrough biologic therapy for sickle cell disease, available for B2B pharmaceutical distribution across the US and EU markets. It is a humanized monoclonal antibody (anti-P-selectin) used to reduce the frequency of painful vaso-occlusive crises in patients with sickle cell anemia. Approved by the FDA and EMA, Crizanlizumab is supplied as a 100 mg/10 mL IV infusion, ideal for hospital and specialty clinic use. Pharma B2B partners benefit from secure supply chains, regulatory-compliant sourcing, and access to one of the most innovative therapies in hematology. Reliable distribution and market-ready packaging ensure smooth commercialization across regulated markets.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Deferoxamine

Strength: 500 mg/vial, 2 g/vial

Form: Lyophilized powder for injection

Reference Brands: Desferal

View Details Get Enquiry
Deferasirox

Strength: 125 mg, 250 mg, 500 mg

Form: Tablets for Oral Suspension

Reference Brands: Exjade, Jadenu (film-coated)

View Details Get Enquiry
Iron(III)-Isomaltoside Injection

Strength: 100mg/ml

Form: Injection

Reference Brands: Monofer,, Diafer, Monoferric

View Details Get Enquiry
Iron Dextran

Strength: 50 mg/mL

Form: injection

Reference Brands: Dexferrum,INFeD

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.